By W. John Martin, MD, PhD., Institute of Progressive Medicine
Vaccination is intended to stimulate the body’s immune response against specific microorganisms or their toxic products. Vaccination is typically the administration via injection of non-living, or otherwise attenuated (weakened), microorganisms or antigenic products, along with an adjuvant intended to enhance the recipient’s immune response. With the exception of attenuated viruses (which typically replicate over a period of a few days after inoculation), repeat doses of each vaccine are usually given to ensure an adequate immune response. By doing so, vaccination can ordinarily reduce the level of illness which would otherwise occur upon encountering the living microorganism by environmental exposure.
While generally considered to be safe, immune responses generated by vaccination can actually contribute to the cellular damage that can accompany an infection. In a small percentage of individuals, prior vaccination can lead to a more severe illness when exposed to the vaccine-relevant microorganisms than if the person had not been previously immunized. Another concern is that occasionally, the immune stimulation elicited by vaccination can trigger or augment an autoimmune response directed inwardly at the recipient’s own tissues.
Another potential hazard to those being vaccinated could come from a pre-existing infection with stealth adapted viruses. These viruses lack the relatively few, major ctitical antigens that are normally targeted in the corresponding conventional virus from which they are derived*. Consequently, little or no cellular immune response normally accompanies stealth adapted viral infections, which may persist over many years. The heightened immune response induced by vaccination can potentially trigger tissue damaging reactions against remaining minor antigens expressed by stealth adapted virus infected cells.
Because of its regional separation of functions, the brain is particularly prone to clinical illnesses caused by stealth adapted viruses. This unique susceptibility to localized cellular damage probably accounts for the predominance of neurological and psychiatric symptoms in the majority of individuals experiencing prolonged severe adverse vaccine reactions. A suitable descriptive term for this condition is “vaccine provocation of stealth adapted virus induced encephalopathy,” or VP-SAVIE.
Autism following vaccination in infants is possibly a prime example of VP-SAVIE. Undue focus on the vaccine, rather than on a potentially pregnancy acquired pre-existing stealth adapted viral infection, has unfortunately distracted many within the autism community.
Similarly, the tragic deterioration in the health of some adolescent recipients of human papillomavirus (HPV) vaccines is likely to be attributed to the provocation of a pre-existing stealth adapted viral infection.
When stealth adapted viruses were first brought to the attention of Public Health authorities, they actively resisted open discussions because one of the earliest stealth adapted viruses discovered arose from the African green monkey simian cytomegalovirus (SCMV). Monkeys infected with SCMV were knowingly used in the production of live polio virus vaccines, a sad commentary on the diligence of the Food and Drug Administration (FDA).
An important insight gained from the study of stealth adapted viruses is that the body can resist viral infections without the participation of the cellular immune system. This non-immunological defense and healing mechanism involves the alternative cellular energy (ACE) pathway and occurs in the absence of inflammation or scarring.
As published over five years ago, the ACE pathway can be effectively activated in the sustained suppression of conventional herpes simplex virus (HSV) and herpes zoster virus (HZV) infections. These experimental protocols were further developed for testing in children with autism.
Simple screening methods are also being developed to potentially monitor the levels of activity of the ACE pathway. A reasonable suggestion is that vaccines should not be administered to anyone in whom the ACE pathway is not fully functional. This issue needs to be urgently addressed by the Public Health system. They hold the key to allow further clinical testing to proceed. Answers need to be uncovered.
Patient support groups and advocates could help by promoting internet based dialogue among themselves and Public Health officials on the issues of stealth adapted viruses and the ACE pathway.
The author would be pleased to participate in any such dialogues.
Email the author at firstname.lastname@example.org
*[note: human cytomegalovirus is composed of nearly 200 genes, yet only a single protein, termed UL83, leads to activation of approximately 60% of the entire cytotoxic T-cell response, with two additional proteins accounting for another 30% of the cellular immune response.]